Deutsche Bank
NVLN

Deutsche Bank’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Deutsche Bank’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-19,078
Closed -$70K – 5668
2018
Q2 		$70K Sell
19,078
-2,904
-13% -$11.7K ﹤0.01% 4674
2018
Q1 		$76K Sell
21,982
-14,493
-40% -$61.4K ﹤0.01% 4618
2017
Q4 		$112K Buy
36,475
+16,521
+83% +$79.4K ﹤0.01% 4225
2017
Q3 		$139K Sell
19,954
-60,280
-75% -$483K ﹤0.01% 4044
2017
Q2 		$740K Sell
80,234
-92,688
-54% -$893K ﹤0.01% 3214
2017
Q1 		$1.86M Buy
172,922
+76,503
+79% +$782K ﹤0.01% 2289
2016
Q4 		$811K Buy
+96,419
New +$854K ﹤0.01% 2846

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Deutsche Bank's NVLN Position: Q3 2018 in Review

Deutsche Bank sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2018, closing a stake of 19,078 shares — an estimated $70K sold.

Deutsche Bank first reported a position in NVLN in Q4 2016 and held it in 7 quarters. The position peaked at $1.86M in Q1 2017. 49 funds tracked by Wall St. Rank hold NVLN as of Q3 2018.

  • Deutsche Bank reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2018 after selling out during the quarter.
  • Deutsche Bank sold 19,078 Novelion Therapeutics Inc. Common Shares shares in Q3 2018, an estimated $70K.
  • Deutsche Bank first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 7 quarters.
  • Deutsche Bank's Novelion Therapeutics Inc. Common Shares position peaked at $1.86M in Q1 2017.
  • 49 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2018.

Based on Deutsche Bank's 13F filing for Q3 2018, filed 14 Nov 2018.